Cancer Therapy AdvisorSome Top-Selling Cancer Drugs May Confer Little or No Therapeutic Benefit

This study analyzes the therapeutic benefit versus cost of the 50 top-selling cancer drugs in the US Medicare system, using benefit ratings from European regulatory bodies. The research indicates a concerning discrepancy between therapeutic value and drug pricing, particularly for medications providing low or no clinical benefit.

⚕️Key Clinical Considerations⚕️

• 80% (39/49) of rated top-selling cancer drugs provided high therapeutic benefit, while 18% (9/49) showed low benefit and 2% (1/49) demonstrated no added benefit.
• Post-rebate Medicare spending was $26.0 billion for high-benefit drugs, $6.4 billion for low-benefit drugs, and $275 million for the no-benefit drug.
• Median spending per beneficiary was paradoxically higher for low-benefit drugs ($70,524) compared to high-benefit drugs ($61,277).
• Six cancer drugs exceeded $100,000 in annual spending per beneficiary, with one of these (palbociclib/Ibrance) classified as having low added therapeutic benefit.
• Researcher-identified factors driving utilization of low-value medications include pharmacy benefit manager incentives, prescriber cost unawareness, and direct-to-consumer advertising.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Discuss both clinical benefits and financial toxicity when recommending cancer treatments, particularly for medications with questionable therapeutic value. Explore alternative evidence-based therapies when data suggests minimal added benefit from high-cost medications.
• Practice Integration: Consider incorporating therapeutic benefit ratings from international regulatory bodies (like Germany’s Federal Joint Committee) when developing institutional formularies and treatment pathways. Implement systematic cost-effectiveness discussions during tumor board reviews for drugs with marginal benefits.
• Risk Management: Document shared decision-making conversations regarding treatments with low therapeutic benefit to ensure patients understand potential limitations.
• Action Items: Review current prescribing patterns for identified low-benefit cancer drugs within your practice. Advocate for policy changes that better align drug pricing with demonstrated clinical value.

More on Healthcare Costs